US Panel Reviews Hyped Peptides Amid Safety and Efficacy Concerns

Peptides, substances promising enhanced well-being from glowing skin to sharper minds, are under scrutiny as a US review panel convenes to consider their recommendation for compounding. The Food and Drug Administration (FDA) panel is set to deliberate on seven peptides, including BPC-157, TB-500, and Semax, which have gained significant traction among influencers and celebrities.

However, many medical experts express strong reservations. "There's just not enough clinical data to say whether these peptides are safe and effective," stated Alexander Weber, an orthopedic surgeon and chief of sports medicine at the University of Southern California. He noted that despite the lack of robust evidence, conversations about peptides are frequent with his patients.

“

There's just not enough clinical data to say whether these peptides are safe and effective.

The substances in question were previously restricted from compounding by the Biden administration due to a lack of human clinical trial data. Despite these restrictions, their use persists, with individuals purchasing them online from chemical suppliers, often labeled "for lab use only." Critics argue that these restrictions have inadvertently fueled a gray market of overseas suppliers operating without oversight or quality standards.

“

With the gray market you have no idea if you're getting a good product.

Concerns have also been raised about the composition of the FDA advisory panel itself. Peter Lurie, president of the Center for Science in the Public Interest, suggested that the panel might be influenced by individuals with strong ties to the peptide industry, given President Donald Trump's health chief Robert F. Kennedy Jr.'s personal interest and use of peptides. Lurie expressed a lack of confidence in the panel's impartiality under these circumstances.

Peptides are naturally occurring amino acid chains that act as signaling molecules in the body. While some well-studied peptides, like insulin and GLP-1 medications such as Ozempic, have established safety and efficacy, the synthetic versions promoted for optimization have not undergone rigorous large-scale trials. The FDA's own scientists have voiced concerns about the inadequacy of evidence supporting the loosening of restrictions on these trendy, often injectable, substances.

“

In ordinary circumstances, I would say that these products are dead. But given the way that the committee is stacked, I don't have that confidence at all.